查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575457

腦炎藥物市場：按治療類型、疾病類型、給藥途徑、患者人口統計、最終用戶、藥物類別和購買類型 - 2025-2030 年全球預測

Encephalitis Treatment Market by Treatment Type, Disease Type, Route of Administration, Patient Demographics, End-User, Drug Class, Mode of Purchase - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年腦炎治療市值為143.2億美元，預計到2024年將達到154.9億美元，複合年成長率為6.59%，到2030年將達到223.9億美元。

腦炎治療市場包括腦部發炎，腦部發炎通常由病毒感染引起。治療包括抗病毒治療、皮質類固醇和支持性治療。這是必要的，因為腦炎可能危及生命，並可能導致嚴重的併發症，如癲癇、認知障礙和神經病變。最終用途主要針對被診斷為腦炎的患者和參與神經照護的醫療保健專業人員。關鍵的成長要素包括病毒感染疾病發生率的增加、診斷技術的進步以及導致早期診斷的意識的提高。新的潛在機會在於開發更準確、更有效的抗病毒藥物和個人化醫療方法，這代表著向基於基因譜和免疫反應的客製化治療計劃的轉變。

主要市場統計
基準年[2023] 143.2億美元
預測年份 [2024] 154.9億美元
預測年份 [2030] 223.9億美元
複合年成長率（%） 6.59%

市場洞察凸顯了區域流行病學調查對於識別高風險地區的重要性，從而促進了對創新診斷工具和治療方案的需求。官民合作關係和政府資助也為研發提供了成長機會。然而，挑戰包括由於腦炎與其他神經系統疾病的症狀重疊而準確診斷腦炎的複雜性，以及與先進診斷程序相關的高成本。此外，低收入地區的意識低和缺乏熟練的醫療保健專業人員也影響了市場的成長。

具有業務成長潛力的創新治療領域包括開發快速診斷試劑套件和遠端醫療解決方案，以擴大偏遠地區的覆蓋範圍並改善早期檢測和治療的可及性。市場的本質是競爭和技術主導，重點是整合人工智慧和機器學習以提高診斷準確性和治療效果。公司可以透過投資研發夥伴關係、利用數位平台進行教育宣傳活動以及提高對腦炎治療方案的認知來保持競爭力並確保抓住不斷變化的市場需求。

市場動態：揭示快速發展的腦炎藥物市場的關鍵市場洞察

供需的動態交互作用正在改變腦炎藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 腦炎症狀的全球流行增加了對有效治療方案的需求
    • 擴大醫療基礎設施和服務可改善腦炎診斷和治療的機會
    • 醫學研究的進步有助於創新解決方案的開發
    • 提高對腦​​炎症狀和治療的認知有助於早期診斷和治療性介入
  • 市場限制因素
    • 治療費用上漲
  • 市場機會
    • 對腦炎早期檢測和管理的先進診斷工具的需求不斷成長
    • 製藥公司與學術機構合作創新腦炎治療方法
    • 增加新解決方案的研發投入
  • 市場挑戰
    • 診斷和鑑別診斷的複雜性

波特五力戰略工具駕馭腦炎藥物市場

波特的五力框架是了解腦炎藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對腦炎藥物市場的影響

外部宏觀環境因素在塑造腦炎治療藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解腦炎治療藥物市場的競爭狀況

腦炎治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣腦炎治療市場供應商的績效評估

FPNV 定位矩陣是評估腦炎治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪腦炎治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對腦炎治療藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 腦炎的盛行率在世界各地不斷增加，增加了對有效治療方法的需求。
      • 擴大醫療基礎設施和服務可改善腦炎診斷和治療的機會
      • 醫學研究的進步有助於開發創新的腦炎藥物解決方案
      • 提高對腦​​炎症狀和治療的認知有助於早期診斷和治療性介入
    • 抑制因素
      • 治療費用高
    • 機會
      • 對腦炎早期檢測和管理的先進診斷工具的需求不斷成長
      • 製藥公司與學術機構合作創新腦炎治療方法
      • 加腦炎新藥方案研發投入
    • 任務
      • 診斷和鑑別診斷的複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章腦炎治療藥物市場：依治療類型

  • 抗病毒藥物
  • 皮質類固醇
  • 免疫療法
  • 支持性護理

第7章腦炎治療藥物市場：依疾病類型

  • 自體免疫腦炎
    • 抗NMDA受體腦炎
    • 橋本腦病變
    • 邊緣葉腦炎
  • 傳染性腦炎
    • 細菌性腦炎
    • 黴菌性腦炎
    • 寄生性腦炎
    • 病毒性腦炎

第8章腦炎治療藥物市場：依給藥途徑

  • 肌肉注射
  • 靜脈
  • 口服

第9章 腦炎治療藥物市場：病人分層

  • 成人用
  • 老年病
  • 小兒科

第10章腦炎治療藥物市場：依最終使用者分類

  • 診所
  • 家庭護理設置
  • 醫院
  • 研究所

第11章腦炎治療藥物市場：依藥物類別

  • 抗病毒藥物
    • 阿昔洛韋
    • 膦甲酸
    • 更昔洛韋
  • 皮質類固醇
    • 地塞米松
    • 強的松
  • 免疫球蛋白
    • IVIG

第12章腦炎治療藥物市場：按購買類型

  • 在商店
  • 處方箋

第13章：北美和南美腦炎治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太腦炎藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章歐洲、中東和非洲腦炎治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議
Product Code: MRR-535C629188F4

The Encephalitis Treatment Market was valued at USD 14.32 billion in 2023, expected to reach USD 15.49 billion in 2024, and is projected to grow at a CAGR of 6.59%, to USD 22.39 billion by 2030.

The scope of the encephalitis treatment market involves diagnosing and managing inflammation of the brain, often due to viral infections. Treatment includes antiviral therapies, corticosteroids, and supportive care. The necessity stems from the potentially life-threatening nature of encephalitis, which can result in severe complications such as seizures, cognitive impairments, or neurological deficits. The application scope extends to hospitals, neurology clinics, and research institutions, while end-use is predominantly patients diagnosed with encephalitis and healthcare professionals involved in neurological care. Key growth factors include increased incidence of viral infections, advancements in diagnostic techniques, and heightened awareness leading to early diagnosis. Emerging potential opportunities lie in the development of more precise and efficient antiviral drugs and personalized medicine approaches, indicating a shift towards tailored treatment plans based on genetic profiling and immune response.

KEY MARKET STATISTICS
Base Year [2023] USD 14.32 billion
Estimated Year [2024] USD 15.49 billion
Forecast Year [2030] USD 22.39 billion
CAGR (%) 6.59%

Market insights highlight the importance of regional epidemiological studies to identify high-risk areas, contributing to the demand for innovative diagnostic tools and treatment options. Public-private partnerships and government funding also present growth opportunities in research and development. However, challenges include the complexity in accurately diagnosing encephalitis due to overlapping symptoms with other neurological conditions and the high costs associated with advanced diagnostic procedures. Limitations in terms of limited awareness in low-income areas and the shortage of skilled healthcare professionals also affect market growth.

Innovative areas poised for business growth include the development of rapid diagnostic kits and telemedicine solutions to expand reach in remote areas, improving early detection and treatment accessibility. The market's nature is competitive and technology-driven, with a focus on integrating AI and machine learning to enhance diagnostic accuracy and treatment efficacy. Companies are encouraged to invest in R&D partnerships and leverage digital platforms for educational campaigns to raise awareness about encephalitis treatment options, ensuring they remain competitive and are capturing evolving market demands.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Encephalitis Treatment Market

The Encephalitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of encephalitis conditions globally increases demand for effective treatment options
    • Expansion of healthcare infrastructure and services enhances access to encephalitis diagnosis and therapies
    • Advancements in medical research contribute to the development of innovative encephalitis treatment solutions
    • Increasing awareness about encephalitis symptoms and treatment boosts early diagnosis and therapeutic interventions
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Growing demand for advanced diagnostic tools for early detection and management of encephalitis
    • Collaborations between pharmaceutical companies and academic institutions for innovative encephalitis therapies
    • Increasing investment in research and development for novel encephalitis treatment solutions
  • Market Challenges
    • Complexity in diagnosis and differentiation

Porter's Five Forces: A Strategic Tool for Navigating the Encephalitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Encephalitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Encephalitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Encephalitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Encephalitis Treatment Market

A detailed market share analysis in the Encephalitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Encephalitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Encephalitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Encephalitis Treatment Market

A strategic analysis of the Encephalitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Encephalitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, CSL Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Encephalitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Antiviral Medication, Corticosteroids, Immunotherapy, and Supportive Care.
  • Based on Disease Type, market is studied across Autoimmune Encephalitis and Infectious Encephalitis. The Autoimmune Encephalitis is further studied across Anti-NMDA Receptor Encephalitis, Hashimoto's Encephalopathy, and Limbic Encephalitis. The Infectious Encephalitis is further studied across Bacterial Encephalitis, Fungal Encephalitis, Parasitic Encephalitis, and Viral Encephalitis.
  • Based on Route of Administration, market is studied across Intramuscular, Intravenous, and Oral.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Clinics, Homecare Settings, Hospitals, and Research Institutes.
  • Based on Drug Class, market is studied across Antivirals, Corticosteroids, and Immunoglobulins. The Antivirals is further studied across Acyclovir, Foscarnet, and Ganciclovir. The Corticosteroids is further studied across Dexamethasone and Prednisone. The Immunoglobulins is further studied across IVIG.
  • Based on Mode of Purchase, market is studied across Over-The-Counter and Prescription.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of encephalitis conditions globally increases demand for effective treatment options
      • 5.1.1.2. Expansion of healthcare infrastructure and services enhances access to encephalitis diagnosis and therapies
      • 5.1.1.3. Advancements in medical research contribute to the development of innovative encephalitis treatment solutions
      • 5.1.1.4. Increasing awareness about encephalitis symptoms and treatment boosts early diagnosis and therapeutic interventions
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for advanced diagnostic tools for early detection and management of encephalitis
      • 5.1.3.2. Collaborations between pharmaceutical companies and academic institutions for innovative encephalitis therapies
      • 5.1.3.3. Increasing investment in research and development for novel encephalitis treatment solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in diagnosis and differentiation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Encephalitis Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Antiviral Medication
  • 6.3. Corticosteroids
  • 6.4. Immunotherapy
  • 6.5. Supportive Care

7. Encephalitis Treatment Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Autoimmune Encephalitis
    • 7.2.1. Anti-NMDA Receptor Encephalitis
    • 7.2.2. Hashimoto's Encephalopathy
    • 7.2.3. Limbic Encephalitis
  • 7.3. Infectious Encephalitis
    • 7.3.1. Bacterial Encephalitis
    • 7.3.2. Fungal Encephalitis
    • 7.3.3. Parasitic Encephalitis
    • 7.3.4. Viral Encephalitis

8. Encephalitis Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intravenous
  • 8.4. Oral

9. Encephalitis Treatment Market, by Patient Demographics

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Encephalitis Treatment Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare Settings
  • 10.4. Hospitals
  • 10.5. Research Institutes

11. Encephalitis Treatment Market, by Drug Class

  • 11.1. Introduction
  • 11.2. Antivirals
    • 11.2.1. Acyclovir
    • 11.2.2. Foscarnet
    • 11.2.3. Ganciclovir
  • 11.3. Corticosteroids
    • 11.3.1. Dexamethasone
    • 11.3.2. Prednisone
  • 11.4. Immunoglobulins
    • 11.4.1. IVIG

12. Encephalitis Treatment Market, by Mode of Purchase

  • 12.1. Introduction
  • 12.2. Over-The-Counter
  • 12.3. Prescription

13. Americas Encephalitis Treatment Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Encephalitis Treatment Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Encephalitis Treatment Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca plc
  • 5. Bayer AG
  • 6. Biogen Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. CSL Limited
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche Ltd
  • 11. Gilead Sciences, Inc.
  • 12. GlaxoSmithKline plc
  • 13. Johnson & Johnson
  • 14. Merck & Co., Inc.
  • 15. Novartis International AG
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. ENCEPHALITIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ENCEPHALITIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ENCEPHALITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. ENCEPHALITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENCEPHALITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENCEPHALITIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTI-NMDA RECEPTOR ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HASHIMOTO'S ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY LIMBIC ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY BACTERIAL ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FUNGAL ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PARASITIC ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY VIRAL ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ACYCLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FOSCARNET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IVIG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 309. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 319. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 320. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 321. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENC